Vaginal HIV transmission accounts for the majority of new infections worldwide. Currently, multiple efforts to prevent HIV transmission are based on pre-exposure prophylaxis with various antiretroviral drugs. Here, we describe two novel nanoformulations of the reverse transcriptase inhibitor rilpivirine for pericoital and coitus-independent HIV prevention. Topically applied rilpivirine, encapsulated in PLGA nanoparticles, was delivered in a thermosensitive gel, which becomes solid at body temperature. PLGA nanoparticles with encapsulated rilpivirine coated the reproductive tract and offered significant protection to BLT humanized mice from a vaginal high-dose HIV-1 challenge. A different nanosuspension of crystalline rilpivirine (RPV LA), a...
Long-acting nanoformulated antiretroviral therapy (nanoART) can sustain plasma drug levels and impro...
Microbicides are considered a promising strategy for preventing human immunodeficiency virus (HIV-1)...
We thank Gilead Science for provision of tenofovir and Janssen R&D Ireland for provision of darunavi...
Vaginal HIV transmission accounts for the majority of new infections worldwide. Currently, multiple ...
<div><p>Vaginal HIV transmission accounts for the majority of new infections worldwide. Currently, m...
Pre-exposure prophylaxis (PrEP) using antiretroviral drugs (ARVs) has been shown to reduce HIV trans...
Recent iPrEx clinical trial results provided evidence that systemic preexposure prophylaxis (PrEP) w...
Antiretroviral (ARV) drugs have, for many years, been studied and administered in the prevention and...
Antiretroviral therapy (ART) has improved the quality and duration of life for people living with hu...
The increasing global prevalence of human immunodeficiency virus (HIV) is estimated at 36.7 million ...
Antiretroviral therapy (ART) requires lifelong daily dosing to suppress viral replication, restore o...
Thesis (Ph.D.)--University of Washington, 2015-12HIV continues to infect millions of people worldwid...
Successful antiretroviral pre-exposure prophylaxis (PrEP) for mucosal and intravenous HIV-1 transmis...
PURPOSE: Developing and testing of microbicides for pre-exposure prophylaxis and post-exposure prote...
Since the year 2012, 2 million newly diagnosed cases of human immunodeficiency virus (HIV) have been...
Long-acting nanoformulated antiretroviral therapy (nanoART) can sustain plasma drug levels and impro...
Microbicides are considered a promising strategy for preventing human immunodeficiency virus (HIV-1)...
We thank Gilead Science for provision of tenofovir and Janssen R&D Ireland for provision of darunavi...
Vaginal HIV transmission accounts for the majority of new infections worldwide. Currently, multiple ...
<div><p>Vaginal HIV transmission accounts for the majority of new infections worldwide. Currently, m...
Pre-exposure prophylaxis (PrEP) using antiretroviral drugs (ARVs) has been shown to reduce HIV trans...
Recent iPrEx clinical trial results provided evidence that systemic preexposure prophylaxis (PrEP) w...
Antiretroviral (ARV) drugs have, for many years, been studied and administered in the prevention and...
Antiretroviral therapy (ART) has improved the quality and duration of life for people living with hu...
The increasing global prevalence of human immunodeficiency virus (HIV) is estimated at 36.7 million ...
Antiretroviral therapy (ART) requires lifelong daily dosing to suppress viral replication, restore o...
Thesis (Ph.D.)--University of Washington, 2015-12HIV continues to infect millions of people worldwid...
Successful antiretroviral pre-exposure prophylaxis (PrEP) for mucosal and intravenous HIV-1 transmis...
PURPOSE: Developing and testing of microbicides for pre-exposure prophylaxis and post-exposure prote...
Since the year 2012, 2 million newly diagnosed cases of human immunodeficiency virus (HIV) have been...
Long-acting nanoformulated antiretroviral therapy (nanoART) can sustain plasma drug levels and impro...
Microbicides are considered a promising strategy for preventing human immunodeficiency virus (HIV-1)...
We thank Gilead Science for provision of tenofovir and Janssen R&D Ireland for provision of darunavi...